Detalles de la búsqueda
1.
Survey of pharmaceutical industry's best practices around in vitro transporter assessment and Implications for Drug Development: Considerations from the IQ Transporter Working Group.
Drug Metab Dispos
; 2024 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38697852
2.
The Absolute Bioavailability and Absorption, Metabolism, and Excretion of Ipatasertib, a Potent and Highly Selective Protein Kinase B (Akt) Inhibitor.
Drug Metab Dispos
; 51(10): 1332-1341, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37524543
3.
Advancing drug development in pediatric oncology, a focus on cancer biology and targeted therapies: iMATRIX platform.
J Biopharm Stat
; 33(6): 800-811, 2023 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36637189
4.
The effect of BI 409306 on heart rate in healthy volunteers: a randomised, double-blind, placebo-controlled, crossover study.
Eur J Clin Pharmacol
; 78(5): 801-812, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35089373
5.
Evaluation of Ipatasertib Interactions with Itraconazole and Coproporphyrin I and III in a Single Drug Interaction Study in Healthy Subjects.
J Pharmacol Exp Ther
; 378(2): 87-95, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34049965
6.
Calibrating the In Vitro-In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK Models.
Drug Metab Dispos
; 48(12): 1264-1270, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33037044
7.
Contribution of Major Metabolites toward Complex Drug-Drug Interactions of Deleobuvir: In Vitro Predictions and In Vivo Outcomes.
Drug Metab Dispos
; 44(3): 466-75, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26684498
8.
Mass balance, metabolite profile, and in vitro-in vivo comparison of clearance pathways of deleobuvir, a hepatitis C virus polymerase inhibitor.
Antimicrob Agents Chemother
; 59(1): 25-37, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25313217
9.
Defining the Role of Gut Bacteria in the Metabolism of Deleobuvir: In Vitro and In Vivo Studies.
Drug Metab Dispos
; 43(10): 1612-8, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26068924
10.
Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients.
J Pharmacol Exp Ther
; 351(2): 403-12, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25204339
11.
Understanding CYP3A4 and P-gp mediated drug-drug interactions through PBPK modeling - Case example of pralsetinib.
CPT Pharmacometrics Syst Pharmacol
; 13(4): 660-672, 2024 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38481038
12.
Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics.
Pharmaceutics
; 16(4)2024 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38675225
13.
Impact of P-gp inhibition on systemic exposure of pralsetinib and dosing considerations.
Clin Transl Sci
; 17(6): e13818, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38807449
14.
Evaluation of Patient-Centric Sample Collection Technologies for Pharmacokinetic Assessment of Large and Small Molecules.
Clin Pharmacol Ther
; 2024 Apr 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38671563
15.
Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103).
J Clin Pharmacol
; 64(5): 544-554, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38105505
16.
Risk Factors of Hyperglycemia After Treatment With the AKT Inhibitor Ipatasertib in the Prostate Cancer Setting: A Machine Learning-Based Investigation.
JCO Clin Cancer Inform
; 7: e2200168, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37116107
17.
Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer.
Clin Genitourin Cancer
; 21(2): 230-237.e1, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36697317
18.
Drug-Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer.
Pharmaceutics
; 14(10)2022 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36297536
19.
Assessment of cytochrome P450 3A4-mediated drug-drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model.
Cancer Chemother Pharmacol
; 89(5): 707-720, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35428895
20.
Mitigating ipatasertib-induced glucose increase through dose and meal timing modifications.
Clin Transl Sci
; 15(12): 2989-2999, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36197694